# A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

> **NCT00147485** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 37 (actual)

## Conditions studied

- Neoplasms
- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** AG-024322

## Key facts

- **NCT ID:** NCT00147485
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** See Detailed Description
- **Last updated:** 2008-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147485, "A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00147485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*